Shin Nippon Biomedical Laboratories Gestion

Gestion contrôle des critères 2/4

Le PDG Shin Nippon Biomedical Laboratories est Ryoichi Nagata, nommé en Jan1991, a un mandat de 33.83 ans. détient directement 2.46% des actions de la société, d'une valeur de € 9.97M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 9.4 ans.

Informations clés

Ryoichi Nagata

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	33.8yrs
Propriété du PDG	2.5%
Durée moyenne d'occupation des postes de direction	2.4yrs
Durée moyenne du mandat des membres du conseil d'administration	9.4yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Ryoichi Nagata (66 yo)

33.8yrs

Titularisation

JP¥144,061,000

Compensation

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Ryoichi Nagata	President	33.8yrs	JP¥144.06m	2.46% € 10.0m
Fumihiko Makino	Senior Executive Officer	2.8yrs	pas de données	pas de données
Toshiyuki Iwata	Managing Executive Officer	no data	pas de données	pas de données
Shinji Nitanda	Senior MD of Corporate Development & Corporate Tax Administration and Director	2.4yrs	pas de données	pas de données
Kyomi Nagatoshi	Senior Managing Executive Officer	no data	pas de données	pas de données
Ken Takanashi	Executive VP of Group Corporate Management & Global Business & Director	20.4yrs	pas de données	0.090% € 364.3k
Satoshi Matsumoto	Managing Executive Officer & GM of Fisheries Division	less than a year	pas de données	pas de données
Hideshi Tsusaki	Senior MD	1.8yrs	pas de données	pas de données
Terumasa Hirai	Managing Executive Officer & President and Representative Director of SNBL Ina Research Center	no data	pas de données	pas de données
Shu-Ichi Kanazashi	Managing Executive Officer	less than a year	pas de données	pas de données
Eishi Tsunozaki	Senior MD & Director	no data	pas de données	0.043% € 176.3k
Ichiro Nagata	Executive VP	no data	pas de données	40.32% € 163.5m

2.4yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de YB3 est considérée comme expérimentée (ancienneté moyenne 2.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Ryoichi Nagata	President	41.6yrs	JP¥144.06m	2.46% € 10.0m
Shinji Nitanda	Senior MD of Corporate Development & Corporate Tax Administration and Director	14.4yrs	pas de données	pas de données
Kyomi Nagatoshi	Senior Managing Executive Officer	no data	pas de données	pas de données
Ken Takanashi	Executive VP of Group Corporate Management & Global Business & Director	21.9yrs	pas de données	0.090% € 364.3k
Hideshi Tsusaki	Senior MD	10.4yrs	pas de données	pas de données
Eishi Tsunozaki	Senior MD & Director	10.4yrs	pas de données	0.043% € 176.3k
Ichiro Nagata	Executive VP	4.4yrs	pas de données	40.32% € 163.5m
Shinichi Fukumoto	Independent Outside Director	9.4yrs	pas de données	0.00096% € 3.9k
Takashi Yamashita	Independent Outside Director	9.4yrs	pas de données	0.00096% € 3.9k
Tsuyoshi Hanada	Independent Outside Director	4.4yrs	pas de données	0.0098% € 39.9k
Keiko Totani	Independent Outside Director	3.4yrs	pas de données	0.0019% € 7.8k
Chizuru Horishita	Independent Outside Director	less than a year	pas de données	pas de données

9.4yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de YB3 sont considérés comme expérimentés (ancienneté moyenne 9.4 ans).

Shin Nippon Biomedical Laboratories Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2023

No independent directors

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 28, 2022

No independent directors

Recent updates

Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without Aura

Second quarter 2025 earnings released: EPS: JP¥29.04 (vs JP¥38.27 in 2Q 2024)

Investor sentiment improves as stock rises 19%

Upcoming dividend of JP¥20.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024

First quarter 2025 earnings released: EPS: JP¥2.94 (vs JP¥32.98 in 1Q 2024)

Investor sentiment deteriorates as stock falls 15%

Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024

Final dividend of JP¥20.00 announced

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024

Full year 2024 earnings released: EPS: JP¥133 (vs JP¥146 in FY 2023)

Upcoming dividend of JP¥30.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024

Third quarter 2024 earnings released: EPS: JP¥19.89 (vs JP¥1.63 loss in 3Q 2023)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

New minor risk - Share price stability

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024

Investor sentiment deteriorates as stock falls 16%

Second quarter 2024 earnings released: EPS: JP¥38.26 (vs JP¥59.45 in 2Q 2023)

Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024

Upcoming dividend of JP¥20.00 per share at 2.6% yield

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: JP¥32.99 (vs JP¥46.70 in 1Q 2023)

Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Now 20% undervalued after recent price drop

Full year 2023 earnings released: EPS: JP¥146 (vs JP¥171 in FY 2022)

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2023

Investor sentiment deteriorates as stock falls 17%

Upcoming dividend of JP¥30.00 per share at 1.4% yield

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: JP¥1.63 loss per share (vs JP¥41.89 profit in 3Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Investor sentiment deteriorated over the past week

No independent directors

Second quarter 2023 earnings released: EPS: JP¥59.45 (vs JP¥40.28 in 2Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: JP¥46.70 (vs JP¥43.86 in 1Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) made a tender offer to acquire Ina Research Inc. (TSE:2176) from its shareholder for ¥2.7 billion.

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: JP¥171 (vs JP¥87.94 in FY 2021)

Shin Nippon Biomedical Laboratories, Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 28, 2022

No independent directors

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2022 Results on May 06, 2022

Upcoming dividend of JP¥40.00 per share

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shin Nippon Biomedical Laboratories, Ltd. Provides Special Dividend Guidance the Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥40.28 (vs JP¥11.91 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS JP¥43.86 (vs JP¥15.45 in 1Q 2021)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2021 and Year Ending March 31, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS JP¥87.94 (vs JP¥61.25 in FY 2020)

Upcoming dividend of JP¥5.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2021 Results on May 10, 2021

New 90-day low: €4.86

Third quarter 2021 earnings released: EPS JP¥8.10 (vs JP¥17.49 in 3Q 2020)

New 90-day high: €5.70